{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:06:11Z","timestamp":1759017971813,"version":"3.44.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"am","delay-in-days":371,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.annder.2023.06.009","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T15:39:10Z","timestamp":1696865950000},"page":"270-273","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A survey of patients with facial angiofibromas associated with tuberous sclerosis complex: Short-, medium- and long-term efficacy and safety of topical rapamycin"],"prefix":"10.1016","volume":"150","author":[{"given":"N.","family":"Sigg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Fouquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Morin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Farges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Vrignaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2023.06.009_b0005","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.pediatrneurol.2003.09.002","article-title":"Tuberous sclerosis complex: genetics to pathogenesis","volume":"29","author":"Narayanan","year":"2003","journal-title":"Pediatr Neurol"},{"issue":"49","key":"10.1016\/j.annder.2023.06.009_b0010","first-page":"243","article-title":"International tuberous sclerosis complex consensus group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the international tuberous sclerosis complex consensus conference","volume":"2013","author":"Northrup","year":"2012","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.annder.2023.06.009_b0015","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1046\/j.1365-2133.2002.04968.x","article-title":"Carbon dioxide and pulsed dye laser treatment of angiofibromas in 29 patients with tuberous sclerosis","volume":"147","author":"Papadavid","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2023.06.009_b0020","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jaad.2007.05.021","article-title":"Sirolimus (rapamycin): from the soil of Easter Island to a bright future","volume":"57","author":"Paghdal","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2023.06.009_b0025","doi-asserted-by":"crossref","first-page":"e0158476","DOI":"10.1371\/journal.pone.0158476","article-title":"Long-term use of everolimus in patients with tuberous sclerosis complex: Final results from the EXIST-1 study","volume":"11","author":"Franz","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.annder.2023.06.009_b0030","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/11634580-000000000-00000","article-title":"Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin","volume":"12","author":"Koenig","year":"2012","journal-title":"Drugs RD"},{"key":"10.1016\/j.annder.2023.06.009_b0035","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0378-6323.190844","article-title":"Topical sirolimus for the treatment of angiofibromas in tuberous sclerosis","volume":"83","author":"Cinar","year":"2017","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.annder.2023.06.009_b0040","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/jamadermatol.2016.3545","article-title":"Efficacy and safety of topical sirolimus therapy for facial angiofibromas in the tuberous sclerosis complex : A randomized clinical trial","volume":"153","author":"Wataya-Kaneda","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2023.06.009_b0045","doi-asserted-by":"crossref","first-page":"omx029","DOI":"10.1093\/omcr\/omx029","article-title":"Topical rapamycin for facial angiofibromas in tuberous sclerosis complex","volume":"2017","author":"Safa","year":"2017","journal-title":"Oxf Med Case Rep"},{"key":"10.1016\/j.annder.2023.06.009_b0050","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/pde.13204","article-title":"Tuberous sclerosis complex in 29 children: Clinical and genetic analysis and facial angiofibroma responses to topical sirolimus","volume":"34","author":"Wang","year":"2017","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.annder.2023.06.009_b0055","first-page":"8404378","article-title":"Sirolimus ointment for facial angiofibromas in individuals with tuberous sclerosis complex","volume":"2017","author":"Amin","year":"2017","journal-title":"Int Sch Res Not"},{"key":"10.1016\/j.annder.2023.06.009_b0060","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jamadermatol.2018.1408","article-title":"Sirolimus gel treatment vs placebo for facial angiofibromas in patients with tuberous sclerosis complex: a randomized clinical trial","volume":"154","author":"Wataya-Kaneda","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2023.06.009_b0065","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jamadermatol.2018.0464","article-title":"Efficacy and safety of topical rapamycin in patients with facial angiofibromas secondary to tuberous sclerosis complex: the treatment randomized clinical trial","volume":"154","author":"Koenig","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2023.06.009_b0070","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.jaad.2018.10.070","article-title":"Topical use of mammalian target of rapamycin inhibitors in dermatology: A systematic review with meta-analysis","volume":"80","author":"Leducq","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2023.06.009_b0075","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1556\/650.2019.31244","article-title":"Successful treatment of facial angiofibromas with local sirolimus in childhood in Bourneville-Pringle disease","volume":"160","author":"Botty\u00e1n","year":"2019","journal-title":"Orv Hetil"},{"key":"10.1016\/j.annder.2023.06.009_b0080","first-page":"1","article-title":"Topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis: a systematic review based on evidence","author":"Cortell Fuster","year":"2021","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.annder.2023.06.009_b0085","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ijpharm.2016.05.064","article-title":"Formulation and characterization of a 0.1% rapamycin cream for the treatment of Tuberous Sclerosis Complex-related angiofibromas","volume":"509","author":"Bougu\u00e9on","year":"2016","journal-title":"Int J Pharm"},{"key":"10.1016\/j.annder.2023.06.009_b0090","doi-asserted-by":"crossref","first-page":"E1060","DOI":"10.3390\/pharmaceutics12111060","article-title":"Comparison of the in vitro and ex vivo permeation of existing topical formulations used in the treatment of facial angiofibroma and characterization of the variations observed","volume":"12","author":"Le Guyader","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.annder.2023.06.009_b0095","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1136\/ejhpharm-2018-001695","article-title":"Long-term stability of 0.1% rapamycin hydrophilic gel in the treatment of facial angiofibromas","volume":"27","author":"Le Guyader","year":"2020","journal-title":"Eur J Hosp Pharm Sci Pract"},{"key":"10.1016\/j.annder.2023.06.009_b0100","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000489089","article-title":"Comparative effects of topical 0.2% sirolimus for angiofibromas in adults and pediatric patients with tuberous sclerosis complex","volume":"234","author":"Lee","year":"2018","journal-title":"Dermatol Basel Switz"},{"key":"10.1016\/j.annder.2023.06.009_b0105","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/bjd.19060","article-title":"Topical rapamycin combined with calcitriol in treating angiofibromas in tuberous sclerosis complex","volume":"183","author":"Lee","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2023.06.009_b0110","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/bjd.18949","article-title":"The efficacy and safety of topical rapamycin-calcitriol for facial angiofibromas in patients with tuberous sclerosis complex: a prospective, double-blind, randomized clinical trial","volume":"183","author":"Chen","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2023.06.009_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmed.2020.00001","article-title":"Early Sirolimus gel treatment may diminish angiofibromas and prevent angiofibroma recurrence in children with tuberous sclerosis complex","volume":"7","author":"Okanishi","year":"2020","journal-title":"Front Med"},{"key":"10.1016\/j.annder.2023.06.009_b0120","doi-asserted-by":"crossref","first-page":"307","DOI":"10.12788\/cutis.0137","article-title":"Combined treatment of disfiguring facial angiofibromas in tuberous sclerosis complex with surgical debulking and topical sirolimus","volume":"106","author":"Patterson","year":"2020","journal-title":"Cutis"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963823000716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963823000716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:11:10Z","timestamp":1758971470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963823000716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0151963823000716"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2023.06.009","relation":{},"ISSN":["0151-9638"],"issn-type":[{"type":"print","value":"0151-9638"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A survey of patients with facial angiofibromas associated with tuberous sclerosis complex: Short-, medium- and long-term efficacy and safety of topical rapamycin","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2023.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}